# Coherus BioSciences

Type: Company (CHRS)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/coherus-biosciences
Canonical HTML page: https://gethealthbrief.com/entity/coherus-biosciences

## Timeline

- **2026-03-08**: Q4 2025 Preview — Analysts set expectations for oncology-driven revenue growth.
- **2025-01-01**: Loqtorzi Launch — Full commercial ramp-up of the first-in-class PD-1 for NPC.
- **2024-06-01**: Yusimry Divestiture — Sale of adalimumab biosimilar to HK King-Friend for $40M.
- **2024-01-01**: Cimerli Divestiture — Coherus sells its ranibizumab biosimilar to Sandoz for $170M.

## Recent coverage (1 stories)

### Coherus BioSciences Q4 Preview: Oncology Pivot and Udenyca Growth in Focus
2026-03-08 22:51:31 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures.
Full story: https://gethealthbrief.com/story/coherus-biosciences-q4-2025-earnings-preview-oncology-pivot

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.